Johnson & JohnsonJNJ

A jury in Massachusetts awarded the family of a woman who died from mesothelioma about 3.3 million dollars, including interest. The case argued that her illness was caused by using the company's talcum-based baby powder for years. While this is a loss in court, the dollar amount is tiny for a company of this size. The real story for owners is the company's broader effort to settle tens of thousands of similar talc-related claims for about 9 billion dollars. This individual verdict is a reminder of the ongoing legal friction, but it does not change the path toward a final, company-wide resolution.

Source: Business Wire

Johnson & Johnson reported that its drug Caplyta met all main goals in a second late-stage study for bipolar mania. Patients saw a rapid improvement in symptoms starting at day three, and the drug was well-tolerated throughout the three-week trial.

This success clears the path for a formal FDA submission. If approved, the drug would treat both the depressive and manic phases of bipolar disorder. Expanding the uses for existing drugs is a key part of the company's plan to replace revenue as older blockbusters lose their patent protection.

Source: PRNewsWire

Mid-stage study data for nipocalimab showed that twice as many patients saw a 50 percent increase in saliva production compared to those on a placebo. Sjögren's disease is an autoimmune condition that causes severe dryness in the mouth and eyes, and there are currently few effective treatments. While these results are promising, the drug is still in Phase 3 testing, which is the final and most rigorous stage of human trials before a drug can be approved. This is one of several immunology treatments the company is counting on to drive growth in the late 2020s.

Source: PRNewsWire

Johnson & Johnson reported encouraging early results for a new dual-targeted immunotherapy called pasritamig. In a small Phase 1 study of patients with advanced prostate cancer, nearly three-quarters of participants saw their PSA levels, a key marker for tracking the disease, drop by at least half. Almost half of the patients saw their levels drop by 90 percent or more.

This treatment is part of the company's push to lead in oncology, which is its fastest-growing business. While the study is still in the early stages, the ability to deliver these results with a dose every six weeks in an outpatient setting could make it a competitive option if later trials confirm these findings.

Source: PRNewsWire

New data from a Phase 3 study shows that icotrokinra, a first-of-its-kind oral peptide, significantly improved symptoms for patients with psoriatic arthritis. About 58 percent of patients taking the once-daily pill saw a meaningful improvement in their joint health after 16 weeks, compared to those on a placebo.

This is a significant development because most high-strength treatments for this condition currently require injections. Offering the same level of effectiveness in a simple daily pill would likely capture significant market share from older, more invasive treatments. As the company faces patent expirations on its older blockbuster drugs, successful launches in the immunology space are critical to maintaining its growth.

Source: PRNewsWire

Metrics we are tracking